Effect of acarbose treatment on the risk of silent myocardial infarctions in patients with impaired glucose tolerance: Results of the randomised STOP-NIDDM trial electrocardiography substudy

European Journal of Preventive Cardiology

Volumn 11, Issue 5, 2004, Pages 412-415

  Zeymer, Uwe ^a   Schwarzmaier D'assie, Alexandra ^b   Petzinna, Dieter ^c   Chiasson, Jean Louis ^d  

^a KLINIKUM LUDWIGSHAFEN   (Germany)

^b KRANKENANSTALT RUDOLFSTIFTUNG   (Austria)

^c BAYER AG   (Germany)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

acarbose impaired glucose tolerance; diabetes mellitus; myocardial infarction; prevention

Indexed keywords

ACARBOSE; PLACEBO;

ADULT; AGED; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFECT; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HYPERGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; POSTPRANDIAL STATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ACARBOSE; ADULT; AGED; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; FEMALE; GLUCOSE INTOLERANCE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; POSTPRANDIAL PERIOD; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 8544240116     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1097/01.hjr.0000140712.71649.5a     Document Type: Article

References (23)

1. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16: 434–444.
2. Hypertension in Diabetes Study (HDS): I. Prevalence of hypertension in newly presenting type II diabetic patients and the association with risk factors for cardiovascular and diabetic complications. J Hypertens 1993; 11: 309–317.
3. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events. A meta-regression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999; 22: 233–240.
4. Hanefeld M, Fischer S, Julius U, Schulze J, Schwanebeck U, Schmechel H,, et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 1996; 39: 1577–1583.
5. Wolever TMS, Chiasson J-L, Csima A, Hunt JA, Palmason C, Ross SA,, et al. Variation of postprandial plasma glucose, palatability, and symptoms associated with a standardized mixed test meal versus 75 g oral glucose. Diabetes Care 1998; 21: 336–340.
6. Haffner SM, Stern MP, Hazuda HP, Mitchell BD, Patterson JK. Cardiovascular risk factors in confirmed pre-diabetic individuals. JAMA 1990; 263: 2893–2998.
7. World Health Organization.Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications: Report of a WHO Consultation. Part I: Diagnosis and Classification of Diabetes Mellitus. 1999. Geneva, World Health Organization.
8. Fuller JH, Shipley MJ, Rose G, Jarrett RJ, Keen H. Coronary-heart-disease risk and impaired glucose tolerance. The Whitehall study. Lancet 1980; i: 1373–1376.
9. Temelkova-Kurktschiev TS, Koehler C, Henkel E, Leonhardt W, Fuecker K, Hanefeld M. Post-challenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbA1c level. Diabetes Care 2000; 23: 1830–1834.
10. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose for prevention of type II diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002; 359: 2072–2077.
11. Blackburn H, Keys A, Simonson E, Rautaharju P, Punsar S. The electrocardiogram in population studies. A classification system. Circulation 1960; 21: 1160–1175.
12. Crow RS, Prineas RJ, Hannan PJ,, et al. Prognostic associations of Minnesota code serial electrocardiographic change classification with coronary heart disease mortality in the Multiple Risk Factor Intervention Trial. Am J Cardiol 1997; 80: 138–144.
13. Menotti A, Mulder I, Kromhout D, Nissinen A, Feskens EJ, Giampaoli S. The association of silent electrocardiographic findings with coronary deaths among elderly men in three European countries. The FINE study. Acta Cardiol 2001; 56: 27–36.
14. Karnegis JN, Matts J, Tuna N, The POSCH Group. Development and evolution of the electrocardiographic Minnesota Q-QS codes in patients with acute myocardial infarction. Am Heart J 1985; 110: 452–459.
15. Chiasson J-L, Gomis R, Hanefeld M, Josse RG, Karasik A, Laakso M. The STOP- NIDDM Trial. An international study on the efficacy of an α-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data. Diabetes Care 1998; 21: 1720–1725.
16. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M and The STOP-NIDDM Trial Research Group Acarbose treatment and the risk of cardiovascular disease and hypertension in subjects with impaired glucose tolerance. The STOP-NIDDM trial. JAMA 2003; 290: 486–494.
17. Sydah SH, Miret M, Sung J, Varas C, Gause D, Brancati FL. Post-challenge hyperglycaemia and mortality in a national sample of U.S. adults. Diabetes Care 2001; 24: 1397–1402.
18. Chiasson J-L, Josse RG, Leiter LA, Mihic M, Nathan DM, Palmason C,, et al. The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance. Diabetes Care 1996; 19: 1191–1194.
19. Ceriello A, Taboga C, Tonutti L, Giacomello R, Stel L, Motz E,, et al. Post-meal coagulation activation in diabetes mellitus: the effect of acarbose. Diabetologia 1996; 39: 469–473.
20. Marfella R, Quagliaro L, Nappo F, Ceriello A, Giugliano D. Acute hyperglycemia induces an oxidative stress in healthy subjects. J Clin Invest 2001; 108: 635–636.
21. Gonzáles-Clemente JM, Ortega-Martinez de Victoria E, Giménez-Palop O, Mauricio D. Acarbose for patients with hypertension and impaired glucose tolerance. Letter to the Editor. JAMA 2003; 290: 3067.
22. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose for patients with hypertension and impaired glucose tolerance. Letter to the Editor. JAMA 2003; 290: 3067–3069.
23. Hanefeld M, Cagatay M, Petrowitsch T, Neuser D, Petzinna D, Rupp M. Acarbose reduces the risk for myocardial infarction in type II diabetes patients: meta analysis of seven long-term studies. Eur Heart J 2004; 25: 10–16.